Study guide
7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation
Key Takeaways Explain This Topic AI
In non-valvular atrial fibrillation, oral anticoagulation decision-making is guided by the CHA2DS2-VASc score; direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran) are preferred over warfarin for patients with a score >=2 in men or >=3 in women.
Warfarin (target INR 2.0-3.0 or 2.5-3.5) remains strictly mandatory for stroke prevention in patients with atrial fibrillation who have moderate-to-severe mitral stenosis or mechanical heart valves.
Hemodynamically unstable atrial fibrillation or supraventricular tachycardia with hypotension, altered mental status, acute pulmonary edema, or ischemic chest pain mandates immediate synchronized direct-current cardioversion.
Administration of AV nodal blocking agents (beta-blockers, CCBs, digoxin, adenosine) is strictly contraindicated in Wolff-Parkinson-White (WPW) syndrome presenting with atrial fibrillation, as blocking the AV node forces rapid conduction down the accessory pathway, precipitating ventricular fibrillation; treatment requires IV procainamide or ibutilide.
Second-degree Mobitz Type II AV block and Third-degree (complete) AV block carry high risks of sudden cardiac arrest and require urgent transcutaneous/transvenous pacing as a bridge to permanent pacemaker implantation.
Last updated: July 2026
Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation
Cardiac arrhythmias encompass a wide spectrum of disorders ranging from benign conduction delays to catastrophic ventricular arrest. On USMLE Step 2 CK, candidates must rapidly analyze EKGs, apply validated clinical scoring tools (such as CHA2DS2-VASc), select appropriate rate versus rhythm control strategies, and execute emergency ACLS resuscitation protocols.
- Atrial Fibrillation & Atrial Flutter
- Atrial Fibrillation (AF) EKG Features & Management
Atrial fibrillation is characterized by irregularly irregular ventricular response , absence of discrete P waves, and irregular fibrillatory baseline waves ( 350 – 600 bpm 350\text{--}600\text{ bpm} 350 – 600 bpm ).
1. Hemodynamic Stability & Acute Resuscitation
Hemodynamically Unstable (hypotension, acute pulmonary edema, ongoing myocardial ischemia): Immediate Synchronized Direct-Current Cardioversion (DCCV) starting at 120–200 J biphasic (with IV heparin bolus).
Hemodynamically Stable: Focus on Rate Control initially using IV or oral beta-blockers (metoprolol, esmolol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) . Target resting heart rate < 110 bpm <110\text{ bpm} < 110 bpm .
2. Stroke Prevention: CHA2DS2-VASc Risk Stratification
CHA2DS2-VASc Risk Criterion Point Value Clinical Definitions & Cutoffs
C — Congestive Heart Failure 1 Signs/symptoms of HF or LVEF ≤ 40 % \le 40\% ≤ 40% .
H — Hypertension 1 Resting BP > 140 / 90 mmHg >140/90\text{ mmHg} > 140/90 mmHg or on antihypertensives.
A2 — Age ≥ 75 \ge 75 ≥ 75 Years 2 Age 75 or older.
D — Diabetes Mellitus 1 Fasting glucose > 126 mg/dL >126\text{ mg/dL} > 126 mg/dL or on anti-diabetics.
S2 — Stroke / TIA / Thromboembolism 2 History of TIA, ischemic stroke, or systemic embolus.
V — Vascular Disease 1 Prior MI, peripheral arterial disease, or complex aortic plaque.
A — Age 65–74 Years 1 Age 65 to 74.
Sc — Sex Category (Female) 1 Female biological sex.
Anticoagulation Decision Rules:
Score 0 in men / 1 in women: No anticoagulation required.
Score 1 in men / 2 in women: Consider oral anticoagulation based on individual clinical risk.
Score ≥ 2 \ge 2 ≥ 2 in men / ≥ 3 \ge 3 ≥ 3 in women: Oral Anticoagulation Mandated.
Drug Selection: Direct Oral Anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over Warfarin due to lower intracranial hemorrhage rates and no monitoring requirements.
Valvular AF Exception: Warfarin (target INR 2.0–3.0, or 2.5–3.5 for mechanical mitral valves) is strictly mandatory for patients with AF and moderate-to-severe mitral stenosis or mechanical heart valves . DOACs are contraindicated in these settings.
3. Cardioversion Timing & Anticoagulation Rules
If AF duration is > 48 hours >48\text{ hours} > 48 hours (or unknown), cardioversion carries a high risk of thromboembolism. Recommendations:
Perform Transesophageal Echocardiogram (TEE) to rule out left atrial/appendage thrombus prior to cardioversion, OR
Anticoagulate for at least 3 consecutive weeks before cardioversion.
All patients require therapeutic anticoagulation for at least 4 weeks post-cardioversion regardless of CHA2DS2-VASc score.
Atrial Flutter
EKG demonstrates regular "sawtooth" flutter waves (F waves) best visualized in inferior leads II, III, and aVF, typically with an atrial rate of ∼ 300 bpm \sim 300\text{ bpm} ∼ 300 bpm and 2:1 AV block (ventricular rate ∼ 150 bpm \sim 150\text{ bpm} ∼ 150 bpm ). Definitive treatment is radiofrequency catheter ablation of the cavotricuspid isthmus (CTI).
- Supraventricular Tachycardias & Pre-Excitation Syndromes
- Regular Narrow-Complex Tachycardias (QRS < 120 ms <120\text{ ms} < 120 ms )
Encompasses AV Nodal Reentrant Tachycardia (AVNRT) and AV Reentrant Tachycardia (AVRT) , presenting with sudden-onset palpitations and HR 150 – 250 bpm 150\text{--}250\text{ bpm} 150 – 250 bpm .
Stable Management: First line is Vagal Maneuvers (modified Valsalva maneuver or carotid sinus massage). Second line is Adenosine 6 mg IV rapid push (followed by 12 mg IV if non-responsive). Adenosine causes transient SA/AV nodal block.
Unstable Management: Immediate Synchronized Cardioversion .
Wolff-Parkinson-White (WPW) Syndrome
Conduction via an accessory pathway (Bundle of Kent) bypassing the AV node.
Classic Resting EKG Triad: Short PR interval ( < 120 ms <120\text{ ms} < 120 ms ), Delta wave (slurred upstroke of QRS), and widened QRS ( > 120 ms >120\text{ ms} > 120 ms ).
WPW with Atrial Fibrillation: Results in an irregular, extremely rapid, wide-complex tachycardia .
CRITICAL CONTRAINDICATION: NEVER administer AV nodal blocking agents (beta-blockers, diltiazem, verapamil, digoxin, adenosine) in WPW with AF! Blocking the AV node promotes 1:1 conduction down the accessory pathway, degenerating into Ventricular Fibrillation .
Treatment of Choice: IV Procainamide or Ibutilide (stable patients), or Synchronized Cardioversion (unstable patients).
- Ventricular Arrhythmias & Channelopathies
- Monomorphic Ventricular Tachycardia (VT)
Wide-complex tachycardia (QRS ≥ 120 ms \ge 120\text{ ms} ≥ 120 ms ) at rates > 100 bpm >100\text{ bpm} > 100 bpm . EKG signs supporting VT over SVT with aberrancy include AV dissociation , capture beats , fusion beats , and concordant QRS pattern across precordial leads.
Stable with Pulse: IV Amiodarone (150 mg IV infusion) or procainamide.
Unstable with Pulse: Synchronized Cardioversion (100 J).
Pulseless VT / Ventricular Fibrillation (VF): Unsynchronized Defibrillation (200 J biphasic) + High-Quality CPR + Epinephrine 1 mg IV q3–5min + Amiodarone 300 mg bolus .
Polymorphic VT / Torsades de Pointes
Associated with prolonged QTc interval ( > 480 – 500 ms >480\text{--}500\text{ ms} > 480 – 500 ms ) . Causes include electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) and QTc-prolonging medications (macrolides, fluoroquinolones, antipsychotics, methadone, class IA/III antiarrhythmics).
Treatment: Intravenous Magnesium Sulfate 1–2 g IV bolus (even if serum magnesium levels are normal). Discontinue offending agents and correct hypokalemia.
Atrioventricular (AV) Conduction Blocks
AV Block Type EKG Manifestations Anatomic Site Management & Prognosis
1st-Degree AV Block Prolonged PR interval ( > 200 ms >200\text{ ms} > 200 ms or > 5 small boxes >5\text{ small boxes} > 5 small boxes ), constant PR, every P wave followed by QRS. AV Node Benign. Observation. No treatment required.
2nd-Degree Mobitz I (Wenckebach) Progressive PR lengthening until a P wave fails to conduct ("long, longer, longest, drop"). AV Node Benign. Usually asymptomatic. Observe; atropine if symptomatic.
2nd-Degree Mobitz II Constant PR interval with unexpected non-conducted P waves ("random dropped QRS"). Sub-nodal (His-Purkinje) High risk of progression to 3rd-degree block. Permanent Pacemaker required.
3rd-Degree (Complete) AV Block Complete dissociation between P waves and QRS complexes. Regular P-P and R-R intervals. Ventricular rate 20–40 bpm. Sub-nodal / His-Purkinje High sudden death risk. Urgent Transcutaneous Pacing bridge to Permanent Pacemaker.